» Articles » PMID: 37430022

Integrated Analyses Reveal the Prognostic, Immunological Features and Mechanisms of Cuproptosis Critical Mediator Gene FDX1 in KIRC

Overview
Journal Genes Immun
Date 2023 Jul 10
PMID 37430022
Authors
Affiliations
Soon will be listed here.
Abstract

The ferredoxin 1 (FDX1) gene had been recently reported as a critical mediator of cuproptosis, and without doubt, its roles in KIRC would be of importance. Hence, this paper was to explore the roles of FDX1 in kidney renal clear cell carcinoma (KIRC) and its potential molecular mechanisms via scRNA-sequencing and bulk RNA-sequencing analyses. FDX1 was lowly expressed in KIRC and validated both at the protein and mRNA levels (all p < 0.05). Moreover, its elevated expression was linked with a better overall survival (OS) prognosis in KIRC (p < 0.01). The independent impact of FDX1 on KIRC prognosis was demonstrated by univariate/multivariate regression analysis (p < 0.01). Gene set enrichment analysis (GSEA) identified seven pathways strongly associated with FDX1 in KIRC. Furthermore, FDX1 was also revealed to be significantly related with immunity (p < 0.05). In addition, patients with low expression of FDX1 might be more sensitive to immunotherapies. ScRNA-seq analysis found that FDX1 could be expressed in immune cells and was mainly differently expressed in Mono/Macro cells. Ultimately, we also identified several LncRNA/RBP/FDX1 mRNA networks to reveal its underlying mechanisms in KIRC. Taken together, FDX1 was closely related to prognosis and immunity in KIRC, and its RBP-involved mechanisms of LncRNA/RBP/FDX1 networks were also revealed by us.

Citing Articles

Cuproptosis in cancer: biological implications and therapeutic opportunities.

Li L, Zhou H, Zhang C Cell Mol Biol Lett. 2024; 29(1):91.

PMID: 38918694 PMC: 11201306. DOI: 10.1186/s11658-024-00608-3.

References
1.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

2.
Shuch B, Amin A, Armstrong A, Eble J, Ficarra V, Lopez-Beltran A . Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2014; 67(1):85-97. DOI: 10.1016/j.eururo.2014.04.029. View

3.
Penticuff J, Kyprianou N . Therapeutic challenges in renal cell carcinoma. Am J Clin Exp Urol. 2015; 3(2):77-90. PMC: 4539109. View

4.
Williamson T, Pearson J, Ischia J, Bolton D, Lawrentschuk N . Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int. 2015; 117(4):555-62. DOI: 10.1111/bju.13384. View

5.
Xie J, Yang Y, Gao Y, He J . Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023; 22(1):46. PMC: 9990368. DOI: 10.1186/s12943-023-01732-y. View